...
首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >Ipsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients
【24h】

Ipsilateral Breast Tumor Reappearance and Contralateral Breast Cancer after Primary Breast Cancer Treatment: A Comprehensive Retrospective Study of 15,168 Patients

机译:原发性乳腺癌治疗后的同侧乳腺肿瘤重新出现和对侧乳腺癌:综合回顾性为15,168名患者

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: The aim of this retrospective study was to assess the risk factors for developing ipsilateral breast tumor reappearance (IBTR) and de novo contralateral breast cancer (BC) after primary BC treatment. Methods: Retrospectively, 15,168 consecutive patients with primary monolateral BC were enrolled in this monocentric study (from June 1994 to December 2006). Clinicopathological features, follow-up, and survival at 15 years were considered for statistical analysis. Results: Significant associations of increased risk for IBTR were verified with metastatic axillary lymph nodes (HR 1.37 [1.15–1.62], p = 0.0004), high tumor grade G2 (HR 1.35 [1.05–1.74], p = 0.02) and G3 (HR 1.35 [1.01–1.79], p = 0.04), luminal B (HR 1.51 [1.25–1.82], p < 0.0001), and HER2-positive (HR1.66 [1.14–2.41], p = 0.008) and triple-negative subtype (HR 1.54 [1.07–2.21], p = 0.02). Older age (HR 1.44 [1.08–1.91], p = 0.01) and positive family history (HR 1.85 [1.47–2.32], p < 0.0001) were risk factors for contralateral BC. Significant protective factors for IBTR were hormonotherapy (HR 0.71 [0.59–0.85], p = 0.0003), chemotherapy (HR 0.72 [0.60–0.87], p = 0.001), and radiotherapy (HR 0.73 [0.61–0.87], p = 0.0005). Hormonotherapy was also confirmed as a protective factor for contralateral second BC (HR 0.43 [0.30–0.60], p < 0.0001). Conclusions: We classified factors for IBTR and contralateral BC in high- and low-risk groups. In the high-risk group, breast surgery still remains more important than in the low-risk group, which seems to benefit more from adjuvant treatments.
机译:目的:这项回顾性研究的目的是评估在原发性BC治疗后开发同侧乳腺肿瘤重新出现(IBTR)和De Novo对侧乳腺癌(BC)的危险因素。方法:回顾性,15,168名初级单身BC患者参加了这项单中心研究(1994年6月至2006年12月)。临床病理特征,随访和15年的存活被认为是统计分析。结果:通过转移性腋窝淋巴结验证了IBTR风险增加的显着联想(HR 1.37 [1.15-1.62],高肿瘤级G2(HR 1.35 [1.05-1.74],P = 0.02)和G3( HR 1.35 [1.01-1.79],P = 0.04),腔B(HR 1.51 [1.25-1.82],P <0.0001)和HER2阳性(HR1.66 [1.14-2.41],P = 0.008)和三倍阴性亚型(HR 1.54 [1.07-2.21],P = 0.02)。年龄较大的(HR 1.44 [1.08-1.91],P = 0.01)和阳性家庭历史(HR 1.85 [1.47-2.32],P <0.0001)是对侧BC的危险因素。 IBTR的显着保护因素是激素治疗(HR 0.71 [0.59-0.85],P = 0.0003),化疗(HR 0.72 [0.60-0.87],P = 0.001)和放射疗法(HR 0.73 [0.61-0.87],P = 0.0005 )。同时也证实了对侧第二BC的保护因子(HR 0.43 [0.30-0.60],P <0.0001)。结论:在高风险群体中,我们为IBTR和对侧BC进行分类。在高风险组中,乳房手术仍然比低风险群体更重要,似乎从佐剂治疗中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号